PT - JOURNAL ARTICLE AU - Plit, ML AU - Anderson, R AU - Van Rensburg, CE AU - Page-Shipp, L AU - Blott, JA AU - Fresen, JL AU - Feldman，C TI -抗菌化疗对肺活量的参数和促炎症指标的影响严重的肺结核DP - 1998年8月01 TA -欧洲呼吸杂志》第六PG - 351 - 356 - 12的IP - 2 4099 - //www.qdcxjkg.com/content/12/2/351.short 4100 - //www.qdcxjkg.com/content/12/2/351.full所以欧元和J19988月1日;12 AB -完成严重肺结核(TB)治疗的患者通常会留下严重的呼吸功能障碍。目前很少有前瞻性研究评估治疗对此类患者肺功能的影响。对新诊断肺结核患者进行为期6个月的抗菌药物化疗对肺功能的影响调查，以验证治疗改善肺功能的假设，并确定可能影响肺功能结局的因素。76名患者被纳入研究，其中74人完成了治疗计划。42人目前是吸烟者，13人人类免疫缺陷病毒血清阳性。54%的患者出现肺功能改善，但分别有28%和24%的患者出现明显的残余气流限制或限制性模式。化疗开始和化疗后肺浸润程度(x线评分)均与1秒用力呼气量(FEV1) (% pred)呈显著负相关(r=-0.41, r=-0.46)。 The post-treatment serum C-reactive protein and alpha1-protease inhibitor levels were negatively associated with FEV1 (% pred) (r=-0.30 and r=-0.35, respectively). These findings demonstrate that, while antimicrobial chemotherapy may lead to improved lung function in patients with pulmonary tuberculosis, a large proportion of patients has residual impairment. The most significant factor influencing post-treatment lung function status, as measured by forced expiratory volume in one second (% predicted), is the pretreatment and post-treatment radiographic score, which acts as a marker of the extent of pulmonary parenchymal involvement in tuberculosis.